Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors

This retrospective study compared the outcomes of sequential therapy using sunitinib followed by axitinib or the mammalian target of rapamycin (mTOR) inhibitors (everolimus or temsirolimus). Among 234 patients treated with molecular-targeted drugs for metastatic renal cell carcinoma, we selected 137...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamada, Satoshi, Iguchi, Taro, Kato, Minoru, Yasuda, Sayaka, Yamasaki, Takeshi, Nakatani, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319347/
https://www.ncbi.nlm.nih.gov/pubmed/30651932
http://dx.doi.org/10.18632/oncotarget.26439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319347/
https://www.ncbi.nlm.nih.gov/pubmed/30651932
http://dx.doi.org/10.18632/oncotarget.26439

Ejemplares similares